A secured, scouted fast-track from discovery to first GMP batches delivered for clinical trials

Many of the decisions made during the early days of building and compiling the manufacturing information for your IND submission will directly impact the future cGMP manufacturing operations and simply become foundational for the commercial viability of the developer’s pipeline of therapies.

Lonza’s Early Advantage program for IND success is designed to arm developers with the tools and expertise to anticipate these future outcomes and challenges, make the best possible educated decisions early-on, all while accelerating the journey to compiling your IND application and starting clinical trials.

Download the Early Advantage white paper

From Bench to IND and first cGMP batches delivered

Tissue
acquisition

  • Tissue acquisition (if applicable)
  • GMP banking (if applicable)

Feasibility

  • Manufacturability
  • GMP feasibility
  • Process definition

Analytics

  • Method development
  • Implementation
  • Stability studies

Process
development

  • Scale studies
  • Yield optimization
  • Small scale toxicology batch

Clinical cGMP material

  • cGMP readiness
  • At scale toxicology batch
  • cGMP batch
  • Regulatory support

A dedicated Bench-to-IND program for your modality

Our Early Advantage Bench to IND Program individually covers all key CGT modalities, from CAR-T therapies, where we have publicly supported key pioneers of the CGT space from early stage to commercial, to Natural Killer (NK) Cells, iPSCs, MSC, Viral vectors including Lentivirus and Adeno-Associated Viruses and Exosomes-based therapies.

Download the white paper

Cell and Gene
Related Insights
techs working in lab
Webinar (on-demand)
Process development best practices for CGT commercialization readiness
Our expert introduces some of the bioprocessing best practices required to de-risk the commercial manufacturing of cell and gene therapies. Watch our...
Webinar (on-demand)
Establishing the Standards of Operational Excellence to Manufacture Commercial Cell Therapies
After entering Phase 3, cell and gene therapies experience nearly five times more discontinuations or significant delays due to CMC issues than...
Webinar on-demand
Webinar (on-demand)
Lonza AAV Suspension Transient Transfection Platform to De-risk Your Path to Clinic
Adeno associated viral vector (AAV) is the delivery vehicle of choice for potentially curative in vivo gene therapy. Following a couple of landmark...
Dev on Demand - CGT - process development
Webinar (on-demand)
Scale-up Allogeneic Cell Therapies to Large Patient Populations
A key benefit of allogeneic cell therapy is that it provides a substantial and economical cost structure, increasing the ability to treat larger...
Video
bluebird bio and Lonza Reflect on Their 10-Year Journey Commercializing Two Gene Therapies
From clinical stages to FDA-approved gene therapies: At the 2023 CAR-TCR Summit in Boston, bluebird bio and Lonza took the opening plenary stage to...
Visit Knowledge Center